Arrivent Biopharma Inc
NASDAQ:AVBP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (38.1), the stock would be worth $15.6 (48% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 73.2 | $29.99 |
0%
|
| 3-Year Average | 38.1 | $15.6 |
-48%
|
| 5-Year Average | 38.1 | $15.6 |
-48%
|
| Industry Average | 1.5 | $0.61 |
-98%
|
| Country Average | 1.5 | $0.61 |
-98%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| US |
A
|
Arrivent Biopharma Inc
NASDAQ:AVBP
|
1.3B USD | 73.2 | -7.7 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
285.6B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 1 028.6 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
100.2B ZAR | 0.9 | 10.4 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
67.9B USD | 1 656.4 | 38 368.9 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
59.7B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
38.4B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
31.4B EUR | 6.1 | 173.5 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.5B USD | 36.9 | -3 256.9 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
29.7B ZAR | 1 | 6.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.9 |
| Median | 1.5 |
| 70th Percentile | 2.9 |
| Max | 566 432.7 |
Other Multiples
Arrivent Biopharma Inc
Glance View
Arrivent Biopharma Inc is a US-based company operating in industry. The company is headquartered in Newtown Square, Pennsylvania and currently employs 40 full-time employees. The company went IPO on 2024-01-26. ArriVent Biopharma, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. Its lead development candidate, Furmonertinib, and advance a pipeline of novel therapeutics, such as antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. Furmonertinib is an oral, highly brain-penetrant, active mutation-selective EGFR inhibitor that targets both classical (exon 19 deletion and L858R) and uncommon EGFR mutations, including exon 20 insertion mutations, as well as HER2 exon 20 insertion mutations. Furmonertinib is an investigational, novel, EGFR mutant-selective tyrosine kinase inhibitor that is developing for the treatment of NSCLC patients across a set of EGFR mutations. The company is also focused on development and commercialization of the ARR-002 program.
